Results 61 to 70 of about 119,023 (342)

Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

British Journal of Pharmacology, 2016
We conducted preclinical and clinical studies to examine the pharmacological, particularly cardiac, effects of amiselimod (MT‐1303), a second‐generation sphingosine 1‐phosphate (S1P) receptor modulator, designed to reduce the bradycardia associated with ...
K. Sugahara, Y. Maeda, K. Shimano, A. Mogami, H. Kataoka, Keiichirou Ogawa, Kumiko Hikida, H. Kumagai, Mahoko Asayama, Toshinobu Yamamoto, T. Harada, P. Ni, Shinsuke Inoue, A. Kawaguchi   +13 more
semanticscholar   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Factores pronósticos de la mortalidad por traumatismo craneoencefálico grave Prognosis factors of mortality due to severe cranioencephalic trauma

Medisan, 2011
Se efectuó un estudio analítico observacional, de tipo caso-control, de los pacientes atendidos en el cuerpo de guardia y posteriormente ingresados en el Hospital Provincial Docente "Saturnino Lora" de Santiago de Cuba desde enero de 2009 hasta diciembre
Rafael Domínguez Peña, Ricardo Hodelín Tablada, Marco Antonio Fernández Aparicio   +2 more
doaj  

Bradycardia

Definitions, 2019
Bradycardia is strictly defined in adults as a pulse rate below 60 beats per minute (bpm). However, few individuals are symptomatic unless the heart rate is below 50 bpm.
Amanda K. Brown, R. Alexis
semanticscholar   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation

Drug Design, Development and Therapy, 2017
Rasmus Rivinius,1 Matthias Helmschrott,1 Arjang Ruhparwar,2 Fabrice F Darche,1 Dierk Thomas,1 Tom Bruckner,3 Hugo A Katus,1 Andreas O Doesch1 1Department of Cardiology, Angiology and Pneumology, 2Department of Cardiac Surgery, Heidelberg University ...
Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO   +7 more
doaj  

Initial Use of 100% but Not 60% or 30% Oxygen Achieved a Target Heart Rate of 100 bpm and Preductal Saturations of 80% Faster in a Bradycardic Preterm Model

Children, 2022
Background: Currently, 21–30% supplemental oxygen is recommended during resuscitation of preterm neonates. Recent studies have shown that 58% of infants < 32 week gestation age are born with a heart rate (HR) < 100 bpm.
Mausma Bawa, Sylvia Gugino, Justin Helman, Lori Nielsen, Nicole Bradley, Srinivasan Mani, Arun Prasath, Clariss Blanco, Andreina Mari, Jayasree Nair, Munmun Rawat, Satyan Lakshminrusimha, Praveen Chandrasekharan   +12 more
doaj   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Intermittent Loss of Telemetry Data

JACC: Case Reports, 2021
We present the case of a 63-year-old female patient who presented to the pacemaker clinic for a scheduled interrogation of her leadless pacemaker. The device interrogation was suggestive of intermittent under-sensing with failure to pace.
Dimitrios Katsaras, MD, Christopher Cassidy, MD, Mohammed Lakha, BSc(Hons), Dawn Gordon, BSc(Hons), Grahame Goode, MD, Khalid Abozguia, PhD   +5 more
doaj  

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source